Document is current

Article History

Received: 25 September 2024

Accepted: 4 December 2024

First Online: 24 December 2024

Declarations

:

: Jacques Beltrand has received speaker Honoraria from Abbott, Medtronic, Lilly, Sanofi Winthrop, Ypsomed, Merckx and Novo Nordisk and served on advisory board panels for Sanofi Winthrop, Medtronic, Insulet and Lilly. Pierre-Yves Benhamou. has received speaker honoraria from Abbott, Eli Lilly, Novo Nordisk and Sanofi, is chief medical officer for Diabeloop, and served on advisory board panels for Abbott, Dexcom, Insulet, LifeScan, Eli Lilly, Pharmasens, Novo Nordisk and Sanofi. Carine Choleau has no conflict of interest to declare. Ben Braithwaite has no conflict of interest to declare. Alice Bonin is an employee of Insulet France SAS. Jean-Pierre Riveline is an advisory panel member for Sanofi, MSD, Eli Lilly, Novo Nordisk, AstraZeneca, Abbott, Dexcom, Alphadiab, and Medtronic, and has received research funding and provided research support to Abbott, Air Liquide, Sanofi, and Novo Nordisk.

: This study was not subject to approval from a regulatory ethics committee, in accordance with article R1121-1 of the French Public Health Code. However, the questionnaire was reviewed by a French scientific committee of diabetes specialists. All procedures in this study complied with the laws and regulations regarding the management of personal information applicable in France, as well as the European General Data Protection Regulation. The study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practices and the Declaration of Helsinki [].

: Informed consent was obtained from all users (person with diabetes or their legal guardian, as appropriate) in the form of a non-opposition statement before showing the questionnaire, as required by article R1121-1 of the French Public Health Code. The information notice also stated that the overall results of the survey, which will be fully anonymized, will be available on the partners’ websites.